140 related articles for article (PubMed ID: 9437715)
21. Effect of introduction of an arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors.
Gourlet P; Vandermeers A; Vandermeers-Piret MC; De Neef P; Waelbroeck M; Robberecht P
Biochim Biophys Acta; 1996 Dec; 1314(3):267-73. PubMed ID: 8982281
[TBL] [Abstract][Full Text] [Related]
22. Binding sites for pituitary adenylate cyclase activating polypeptide (PACAP): comparison with vasoactive intestinal polypeptide (VIP) binding site localization in rat brain sections.
Masuo Y; Ohtaki T; Masuda Y; Tsuda M; Fujino M
Brain Res; 1992 Mar; 575(1):113-23. PubMed ID: 1324082
[TBL] [Abstract][Full Text] [Related]
23. Sequences (103-110) and (116-120) of the rat secretin receptor are implicated in secretin and VIP recognition.
Robberecht P; Di Paolo E; Moguilevsky N; Bollen A; Waelbroeck M
Ann N Y Acad Sci; 2000; 921():362-5. PubMed ID: 11193853
[No Abstract] [Full Text] [Related]
24. The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors.
Gourlet P; Vilardaga JP; De Neef P; Waelbroeck M; Vandermeers A; Robberecht P
Peptides; 1996; 17(5):825-9. PubMed ID: 8844773
[TBL] [Abstract][Full Text] [Related]
25. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions.
Usdin TB; Bonner TI; Mezey E
Endocrinology; 1994 Dec; 135(6):2662-80. PubMed ID: 7988457
[TBL] [Abstract][Full Text] [Related]
26. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors in chick cerebral cortex.
Zawilska JB; Niewiadomski P; Nowak JZ
J Mol Neurosci; 2003 Apr; 20(2):153-62. PubMed ID: 12794309
[TBL] [Abstract][Full Text] [Related]
27. Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors.
Igarashi H; Ito T; Pradhan TK; Mantey SA; Hou W; Coy DH; Jensen RT
J Pharmacol Exp Ther; 2002 Nov; 303(2):445-60. PubMed ID: 12388623
[TBL] [Abstract][Full Text] [Related]
28. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
Xia M; Sreedharan SP; Bolin DR; Gaufo GO; Goetzl EJ
J Pharmacol Exp Ther; 1997 May; 281(2):629-33. PubMed ID: 9152366
[TBL] [Abstract][Full Text] [Related]
29. Construction of chimeras between human VIP1 and secretin receptors: identification of receptor domains involved in selectivity towards VIP, secretin, and PACAP.
Du K; Nicole P; Couvineau A; Laburthe M
Ann N Y Acad Sci; 1998 Dec; 865():386-9. PubMed ID: 9928035
[No Abstract] [Full Text] [Related]
30. Rat and guinea pig pancreatic acini possess both VIP(1) and VIP(2) receptors, which mediate enzyme secretion.
Ito T; Hou W; Katsuno T; Igarashi H; Pradhan TK; Mantey SA; Coy DH; Jensen RT
Am J Physiol Gastrointest Liver Physiol; 2000 Jan; 278(1):G64-74. PubMed ID: 10644563
[TBL] [Abstract][Full Text] [Related]
31. In vitro autoradiographic localization of vasoactive intestinal peptide (VIP) binding sites in the rat central nervous system.
Besson J; Dussaillant M; Marie JC; Rostene W; Rosselin G
Peptides; 1984; 5(2):339-40. PubMed ID: 6089133
[TBL] [Abstract][Full Text] [Related]
32. Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship.
Nicole P; Du K; Couvineau A; Laburthe M
J Pharmacol Exp Ther; 1998 Feb; 284(2):744-50. PubMed ID: 9454823
[TBL] [Abstract][Full Text] [Related]
33. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
34. Interaction of amino acid residues at positions 8-15 of secretin with the N-terminal domain of the secretin receptor.
Gourlet P; Vilardaga JP; De Neef P; Vandermeers A; Waelbroeck M; Bollen A; Robberecht P
Eur J Biochem; 1996 Jul; 239(2):349-55. PubMed ID: 8706739
[TBL] [Abstract][Full Text] [Related]
35. Characterization of vasoactive intestinal peptide receptors in canine liver membranes.
Kiso T; Ito S; Ohta T; Asano T; Nakazato Y
Biochem Pharmacol; 1994 Jan; 47(2):241-5. PubMed ID: 8304967
[TBL] [Abstract][Full Text] [Related]
36. The mouse VPAC2 receptor confers suprachiasmatic nuclei cellular rhythmicity and responsiveness to vasoactive intestinal polypeptide in vitro.
Cutler DJ; Haraura M; Reed HE; Shen S; Sheward WJ; Morrison CF; Marston HM; Harmar AJ; Piggins HD
Eur J Neurosci; 2003 Jan; 17(2):197-204. PubMed ID: 12542655
[TBL] [Abstract][Full Text] [Related]
37. Evidence for multiple rat VPAC1 receptor states with different affinities for agonists.
Busto R; Juarranz MG; De Maria S; Robberecht P; Waelbroeck M
Cell Signal; 1999 Sep; 11(9):691-6. PubMed ID: 10530878
[TBL] [Abstract][Full Text] [Related]
38. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
39. Autoradiographic localization of vasoactive intestinal polypeptide receptors in the rat mesenteric vascular tree.
Amenta F; Cavallotti C; Collier WL; Ferrante F; Geppetti P; Ricci A
Regul Pept; 1989 Aug; 26(1):9-17. PubMed ID: 2554372
[TBL] [Abstract][Full Text] [Related]
40. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
